# MOTS-C Research: What Studies Show and What Is Still Unknown

MOTS-C research is almost entirely preclinical: the peptide has been studied in cultured cells and in mice, and no completed human trial has tested it. This guide separates the evidence that exists from the claims made about it — what the 2015 discovery paper found, what the exercise study actually measured, why CB4211 is not MOTS-C, and which registered human trial has now begun. Supplied for in vitro research purposes only.

- Source: https://www.australianresearchpeptides.au/articles/mots-c-research-trial-tracker
- Reading time: 9 minute read
- Published: 2026-09-02
- Publisher: Australian Research Peptides

---

In vitro research purposes only.

MOTS-C is an experimental compound. No medicines regulator anywhere has approved it for any purpose. Everything below reports published research and public trial registry records. Nothing here is a protocol, an amount or a recommendation, and material supplied by Australian Research Peptides is for in vitro research purposes only.

## What Does the Research on MOTS-C Actually Establish?

MOTS-C research is almost entirely preclinical. The record runs from cell culture through mouse experiments to a small number of human observations, and stops there — no completed trial has given synthetic MOTS-C to people. The table below keeps each kind of evidence in its own row, because the commonest error in this field is reading one row as though it were another.

_The kinds of evidence that exist for MOTS-C, and what each kind cannot establish_

| Kind of evidence | What exists for MOTS-C | What it does not establish |
| --- | --- | --- |
| Cell culture | The 2015 report that first described the peptide, and the 2018 report that traced it into the cell nucleus under metabolic stress | Anything about a whole organism. A cell in a dish has no liver, no bloodstream and no way to clear a peptide |
| Animal studies | The largest part of the record: mice given the peptide in metabolic, skeletal-muscle and mitochondrial experiments, from 2015 through to 2026 | Anything about people. Species differ in metabolism and in how quickly they break a peptide apart |
| Human observation | Measurements of the MOTS-C people already make, taken from muscle and blood around bouts of exercise | Anything about supplying it. Measuring a molecule the body produces is a different experiment from administering one |
| Registered interventional trial | One phase 2a study, registered and under way since February 2026, with no results posted | Anything yet. A trial that has started has answered nothing, and a registration is not a finding |
| Batch analysis | HPLC and mass spectrometry run on the supplied material, reported on a certificate for that batch | Anything the compound does. Identity and purity are separate questions from effect, and a certificate answers only the first |

## What Is MOTS-C?

MOTS-C is a peptide of sixteen amino acids that mitochondria code for themselves. Almost every peptide in a cell is coded by DNA in the nucleus; this one is coded by a short open reading frame inside the mitochondrial 12S ribosomal RNA region. An open reading frame is a run of genetic code that can be read as instructions for a peptide, and peptides coded that way are grouped as **mitochondrial-derived peptides**. The [MOTS-C product page](https://www.australianresearchpeptides.au/products/mots-c) covers the sequence and the naming; this article is about the evidence.

## When Was MOTS-C First Reported?

MOTS-C was first reported in 2015, by Lee and colleagues in Cell Metabolism. That single paper describes the peptide, its route to AMPK and its metabolic effects in mice, so the discovery and the headline animal findings arrived together in one publication. The field is therefore about a decade old, and much of what circulates about MOTS-C traces back to that one paper rather than to separate confirmations of it.

## How Is MOTS-C Proposed to Signal?

MOTS-C is proposed to act through AMPK, the switch a cell throws when its fuel runs low. The 2015 report describes the peptide interfering with part of the folate cycle, which lets a molecule called AICAR build up, and AICAR switches AMPK on. That route was worked out in cells and in mice.

A second mechanism was added in 2018. Kim and colleagues, again in Cell Metabolism, found that under metabolic stress MOTS-C moves into the cell nucleus and changes how strongly stress-response genes are read. A mitochondrial peptide regulating nuclear genes was the surprising part, and it is why the compound is discussed in ageing research rather than only in metabolic research.

A mechanism is not an outcome.

Both findings above describe what the molecule does inside a cell, not what happens to an animal or a person. The 2026 stromal-cell study further down this page is the clearest published case of that gap.

## What Have the Animal Studies Found?

Animal studies are where nearly all of the MOTS-C record sits. In mouse models, administered MOTS-C has been reported to act on insulin sensitivity, on body-weight regulation under a rich diet, and on physical capacity in older animals. Three findings carry most of that weight.

- **2015, metabolic.** In mice, treatment was reported to prevent insulin resistance arising from age and from a high-fat diet, and to prevent diet-induced obesity.
- **2021, physical capacity.** In young, middle-aged and old mice, treatment was reported to increase physical performance. A separate arm began treatment late in life and reported increased physical capacity and healthspan.
- **2026, mitochondrial function.** In two transgenic mouse strains, treatment improved skeletal-muscle mitochondrial performance and lowered reactive oxygen species emission, without changing how much mitochondrial respiratory protein the muscle held.

That last detail is the interesting one. Performance improved while the amount of mitochondrial machinery stayed the same, which points to the existing mitochondria working differently rather than to there being more of them.

## What Human Evidence Exists for MOTS-C?

Human MOTS-C evidence is observational, not interventional. Published studies have measured the MOTS-C that people already produce, in muscle and in blood, around exercise. No completed study has supplied synthetic MOTS-C to people and measured a result.

Those two things are constantly run together, and the confusion has a specific source: the 2021 paper contains both experiments, and its abstract states them in consecutive sentences. Keeping them apart is the single most useful thing a reader can do with this literature.

### Endogenous: What the Exercise Study Measured

The 2021 human experiment measured MOTS-C in ten sedentary healthy young men before and after cycling on an ergometer. Muscle MOTS-C rose almost twelve-fold after the bout and was still raised four hours later. Levels in the blood rose as well.

Read precisely, that says exercise increases the MOTS-C a person makes. It says nothing about the reverse direction. The mouse-treatment arms of the same paper are a different experiment, in a different species, pointing the other way — and no published work joins the two ends into a claim about administering the peptide to a person.

This is the most over-read paper in the field.

It is routinely summarised as showing that MOTS-C reproduces the effects of exercise. It shows that exercise raises MOTS-C in people, and separately that MOTS-C improved physical performance in mice. Those are two findings, and neither of them is that claim.

### The Second Human Observation, and It Is Negative

A 2026 study found no arterio-venous difference in MOTS-C across exercising human muscle, despite MOTS-C rising in the fluid between the muscle cells. Arterio-venous difference is the gap between what enters a tissue in the artery and what leaves it in the vein. A release from that tissue would show up there.

The authors conclude that skeletal muscle may not be the source of the MOTS-C appearing in the circulation during exercise. That complicates the tidy version of the 2021 story, and it rarely reaches secondary coverage because it subtracts rather than adds.

## Is CB4211 the Same as MOTS-C?

No. CB4211 is a separate investigational drug candidate, described in a 2022 review as a MOTS-c analogue — an analogue being a molecule built on the structure of another rather than the same molecule. It was developed by a biotechnology company, and it is not native MOTS-C.

Its trial record is public and repays reading carefully. Registry entry NCT03998514 was a phase 1a/1b study in healthy non-obese volunteers and in adults with non-alcoholic fatty liver disease, with 88 participants enrolled. The record lists it as completed on 19 April 2021.

Two things follow, and both cut the same way. No results are posted on that registry record, and a PubMed search for the drug code returns no publications at all. So the mitochondrial-derived peptide programme that reached people first tested a modified molecule and never published an outcome. It cannot be read as human evidence for MOTS-C on either count.

## Is There a Human MOTS-C Clinical Trial?

Yes — one, and it has not reported. Registry entry NCT07505745 is a phase 2a randomised, double-blind, placebo-controlled study of MOTS-C in adults with prediabetes and overweight or obesity. It began on 2 February 2026 and is the first registered interventional trial of the peptide itself.

_The registered phase 2a MOTS-C trial, as its ClinicalTrials.gov record stood on 2 September 2026_

| Field | What the registry record states |
| --- | --- |
| Registry record | NCT07505745 |
| Phase and design | Phase 2a, randomised one to one, double-blind, placebo-controlled |
| Planned size | 120 participants, listed as an estimate rather than an actual count |
| Population | Adults with prediabetes and overweight or obesity |
| Length | Twelve weeks of once-daily subcutaneous injection, with safety follow-up to week sixteen |
| Started | 2 February 2026, recorded as an actual date |
| Primary completion | 14 February 2027, estimated |
| Study completion | 17 May 2028, estimated |
| Results posted | None |
| Status when read | Recruiting, read from the registry on 2 September 2026 |

Read the last two rows together. The earliest date on the record for a primary outcome is February 2027, so anything quoted today as a human MOTS-C finding does not come from this trial. This trial has produced nothing to quote.

## What Did the 2026 Studies Add?

Two 2026 papers moved the MOTS-C record and they point in opposite directions. One deepened the mouse mitochondrial story; the other is the clearest published counterexample in the field.

The first, in Free Radical Biology and Medicine, reported that in mice the improvement in muscle mitochondrial performance depended on both PGC-1α and AMPK. PGC-1α is a coactivator — a protein that helps switch a set of genes on together. Remove either and the effect went with it, which is a mechanism nailed down rather than assumed.

The second, in Inflammation and Regeneration, is the counterweight. It worked with human adipose-derived mesenchymal stromal cells — repair cells taken from fat tissue — from six donors with obesity and six lean donors. Adding MOTS-C restored the lower baseline levels found in the obese cells and switched AMPK signalling on, exactly as the mechanism predicts.

Then the cells got worse. Proliferation fell, senescence-associated gene expression rose, and an inflammatory signal rose with it. Senescence is the state in which a cell stops dividing but does not die. In a mouse model of renal artery stenosis, cells pre-treated with MOTS-C failed to improve kidney perfusion, fibrosis or tubular injury — and pre-treatment blunted the repair effect of the lean cells too.

Why that paper belongs on this page.

Almost every account of MOTS-C treats AMPK activation as the endpoint. Here the switch went on and the functional result went the wrong way, in human cells, in a study designed to show the opposite. Activation is not benefit, and this is the published case that shows it.

## MOTS-C Research Timeline

_Published MOTS-C research and trial milestones in date order, with the model system used in each_

| Year | What was reported | Model |
| --- | --- | --- |
| 2015 | MOTS-C described, along with its route to AMPK and its metabolic effects | Cells and mice |
| 2018 | The peptide moves into the nucleus under metabolic stress and alters nuclear gene expression | Cells |
| 2021 | Physical capacity improved with treatment; separately, exercise raised endogenous MOTS-C | Mice, plus ten human volunteers |
| 2021 | CB4211 phase 1a/1b completed — an analogue, not MOTS-C, and no results posted | People |
| 2026 | Muscle mitochondrial gains shown to depend on PGC-1α and AMPK; no release detected across exercising human muscle | Mice, plus humans |
| 2026 | AMPK activated in human stromal cells, but proliferation fell, senescence markers rose and repair capacity was lost | Human cells and mice |
| 2026, ongoing | The first registered interventional trial of MOTS-C in people begins | People |

## What Is Still Unknown About MOTS-C?

Almost everything that matters about MOTS-C in people is unknown. This is the section most pages leave out, and it decides how much weight the rest deserves.

- **No completed human trial exists.** Nothing published describes what supplying MOTS-C to a person does.
- **No human pharmacokinetics have been published.** Nobody has reported how quickly a person clears it, which is why no interval quoted anywhere has a source behind it.
- **The source of exercise-induced MOTS-C is unsettled.** The 2026 arterio-venous data argue against skeletal muscle being where the circulating peptide comes from.
- **Effects appear to depend on context.** The same AMPK activation produced improvement in mouse muscle and impairment in human stromal cells.
- **Nothing is published beyond the study durations run.** There is no long-term animal record, and no human record at all.
- **No head-to-head comparison has been published** against humanin or any other mitochondrial-derived peptide.
- **Nothing has been observed after treatment stops.** Every animal measurement was taken during administration.

## What Does ARP Supply?

Australian Research Peptides lists [MOTS-C](https://www.australianresearchpeptides.au/products/mots-c) under Mitochondrial Research as a lyophilised — freeze-dried — powder in a sealed, tamper-evident glass vial, in two strengths. No strength can be ordered at the moment, so what follows names what is catalogued rather than what is on the shelf.

_The MOTS-C vial strengths listed by Australian Research Peptides, with the stock code for each_

| Vial | Stock code |
| --- | --- |
| [10 mg](https://www.australianresearchpeptides.au/products/mots-c/10mg) | ARP-MOTSC-10 |
| [20 mg](https://www.australianresearchpeptides.au/products/mots-c/20mg) | ARP-MOTSC-20 |

Every vial holds the identical sixteen-amino-acid chain, and only the quantity inside differs. No certificate is published for this compound yet. The [certificate library](https://www.australianresearchpeptides.au/coa) lists every strength that has one and every strength still waiting, because a certificate arrives with the batch it describes.

Nothing in the literature above describes the vial itself. Published work characterises the peptide as a molecule; what reaches a laboratory bench is one particular batch, and whether that batch holds what its label says is settled by analysing it rather than by reading any study. [How to read a certificate of analysis](https://www.australianresearchpeptides.au/articles/peptide-testing-purity-coa) sets out which methods answer that question and where they stop.

## Does the Research Prove MOTS-C Improves Human Metabolism or Exercise Performance?

No. No published study has supplied MOTS-C to a person and reported a metabolic or performance result, so no such claim has evidence behind it. What has been shown is that exercise raises the MOTS-C people already make, and that treatment altered metabolism and physical capacity in mice.

The honest position is that MOTS-C is a genuinely interesting mitochondrial peptide with a real preclinical literature, one registered trial under way, and no human result of any kind. Every stronger statement circulating about it is either an animal finding with its species removed, or the 2021 exercise observation read backwards.

## Related Guides

- [Beginner’s guide to research peptidesWhat a peptide is, and how the categories on this site fit together.](https://www.australianresearchpeptides.au/articles/research-peptides-beginners-guide)
- [How to read a certificate of analysisWhat HPLC and mass spectrometry establish about a batch, and what they leave open.](https://www.australianresearchpeptides.au/articles/peptide-testing-purity-coa)
- [Retatrutide and its trial recordThe opposite case: a compound whose evidence is human trials rather than mice.](https://www.australianresearchpeptides.au/articles/retatrutide-mechanism-and-trial-record)
- [In vitro research requirementsWhat research-use supply means for a purchaser in Australia.](https://www.australianresearchpeptides.au/articles/research-use-requirements)

Lyophilised MOTS-C sits under Mitochondrial Research at Australian Research Peptides, with nothing orderable while the shelf is empty, shipped from Sydney as in vitro laboratory material — a supply question, and entirely separate from the evidence question this article is about.

## References

1. [Lee C, Zeng J, Drew BG, et al. Cell Metabolism 2015;21(3):443-454 (PMID 25738459, PMCID PMC4350682)](https://pubmed.ncbi.nlm.nih.gov/25738459/)
2. [Kim KH, Son JM, Benayoun BA, Lee C. Cell Metabolism 2018;28(3):516-524.e7 (PMID 29983246, PMCID PMC6185997)](https://pubmed.ncbi.nlm.nih.gov/29983246/)
3. [Reynolds JC, Lai RW, Woodhead JST, et al. Nature Communications 2021;12(1):470 (PMID 33473109, PMCID PMC7817689)](https://pubmed.ncbi.nlm.nih.gov/33473109/)
4. [Miller B, Kim SJ, Kumagai H, Yen K, Cohen P. Journal of Clinical Investigation 2022;132(9) (PMID 35499074, PMCID PMC9057581)](https://pubmed.ncbi.nlm.nih.gov/35499074/)
5. [Gudiksen A, Hansen CC, van der Stede T, et al. Free Radical Biology and Medicine 2026;246:682-696 (PMID 41520850)](https://pubmed.ncbi.nlm.nih.gov/41520850/)
6. [Xing L, Lu B, Zhu X, et al. Inflammation and Regeneration 2026, online ahead of print (PMID 42324588)](https://pubmed.ncbi.nlm.nih.gov/42324588/)
7. [ClinicalTrials.gov — NCT03998514, CB4211 phase 1a/1b registry record](https://clinicaltrials.gov/study/NCT03998514)
8. [ClinicalTrials.gov — NCT07505745, phase 2a MOTS-c registry record](https://clinicaltrials.gov/study/NCT07505745)
9. [PubChem CID 146675088 — MOTS-c, sixteen-residue sequence](https://pubchem.ncbi.nlm.nih.gov/compound/146675088)

## Related compounds

- [MOTS-C](https://www.australianresearchpeptides.au/products/mots-c)

---

_Plain-text version of https://www.australianresearchpeptides.au/articles/mots-c-research-trial-tracker. The web page is the canonical version of this article._

_All products supplied by Australian Research Peptides are for in vitro research purposes only._